Latest Research And Development News

Delorean Corporation’s SA1 Salisbury renewable gas project is more than 85% complete after the company returned to near break-even EBITDA in FY2026. But the annual report carries a material uncertainty over going concern, leaving commissioning, refinancing and new funding as critical tests for the ASX-listed developer.

Right Resources posted a A$5.16 million loss for FY2026 and warned of material uncertainty over its ability to continue as a going concern, despite A$3.24 million in cash at year-end and a subsequent A$2.94 million capital raise. The explorer is betting that new drilling at Blue and a revised geological model at Pilot can improve the investment case.

Wildcat Resources has entered FY27 with a $60 million placement, a $37.2 million year-end cash balance and its Tabba Tabba lithium project advancing towards a definitive feasibility study. The funding strengthens the development runway, but final investment approval, financing and approvals remain ahead.

Temas Resources has generated its first revenue from its regenerative chloride leaching technology, but the milestone arrives alongside a wider first-half loss, declining cash and an explicit need for further funding by Q4 2026. The company ended June with C$3.39 million in cash and a C$933,940 estimated flow-through tax liability.

Parkway Corporate Limited (ASX:PWN) delivered a sharp revenue increase in FY26 and generated positive operating cash flow, but slipped into a statutory loss and flagged significant uncertainty around its ability to continue as a going concern. Key approvals for its Queensland brine project and a new $2 million mining contract offer commercial progress, while funding remains the central test.

Identitii’s BNDRY platform gained customers and recurring revenue in FY26, but the company ended the year with just $107,483 in cash, negative net assets and a material uncertainty over its ability to continue as a going concern. A subsequent convertible note facility provides a committed $5 million, while access to a further $15 million remains conditional.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.

West Cobar Metals ended FY2026 with more cash but a larger loss and an auditor-highlighted material uncertainty over its ability to continue without further funding. Exploration advanced across Salazar and Cobar West, but the company remains dependent on equity markets to keep its programmes moving.

IperionX has moved its Virginia titanium operation into 24/7 production, lifting nameplate powder capacity to about 200 tonnes a year while commissioning equipment aimed at higher-value components. The progress came alongside a US$66.8 million annual loss, US$63.5 million of operating and investing cash outflows, and continued reliance on government support, customer qualification and future capital.

IODM Limited (ASX:IOD) increased FY2026 revenue by 16.9% and narrowed its net loss, but auditors flagged material uncertainty over the company’s ability to continue as a going concern. A post-year-end A$1.00 million placement is funding an expansion into North American universities while the business remains heavily reliant on external capital.